Who are LEVITRA (vardenafil)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ZYDENA TAB.75mg(Udenafil 75mg), Viagra (sildenafil citrate).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levitra-vardenafil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

LEVITRA (vardenafil) — Competitive Intelligence Brief

LEVITRA (vardenafil) (LEVITRA (vardenafil)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase type 5 (PDE5) inhibitor. Area: Urology / Sexual Health.

marketed Phosphodiesterase type 5 (PDE5) inhibitor PDE5 (phosphodiesterase type 5) Urology / Sexual Health Small molecule Live · refreshed every 30 min

Target snapshot

LEVITRA (vardenafil) (LEVITRA (vardenafil)) — GlaxoSmithKline. Vardenafil inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cyclic GMP levels and promoting smooth muscle relaxation and vasodilation to enable erectile function.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
LEVITRA (vardenafil) TARGET	LEVITRA (vardenafil)	GlaxoSmithKline	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
ZYDENA TAB.75mg(Udenafil 75mg)	ZYDENA TAB.75mg(Udenafil 75mg)	Samsung Medical Center	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
Viagra (sildenafil citrate)	Viagra (sildenafil citrate)	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase type 5 (PDE5) inhibitor class)

GlaxoSmithKline · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LEVITRA (vardenafil) — Competitive Intelligence Brief. https://druglandscape.com/ci/levitra-vardenafil. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab